Abstract
Optimal treatment of oral mucositis (OM) due to graft versus host disease (GvHD) is currently not available. Platelet-derived growth factors (PDGFs) have high capability for tissue healing and may play a role in repairing the mucosal barrier. The aim of the present work was to develop a mucoadhesive formulation to administer platelet lysate to oral cavity prolonging contact time of platelet lysate with oral mucosa. The mucoadhesive formulation was characterized for in vitro properties (PDGF-AB concentration, mucoadhesive properties, cytotoxicity, fibroblast proliferation, wound healing). Moreover, a preliminary clinical study on seven GvHD patients with OM refractory to other therapies was conducted, to evaluate feasibility, safety, and efficacy. GVPL (mucoadhesive gel vehicle mixed with platelet lysate)showed good mucoadhesive properties; additionally, it was characterized by good biocompatibility in vitro on fibroblasts and it was able to enhance fibroblast proliferation and wound healing, maintaining the efficacy for up to 14 days following storage at 2–8°C. In vivo, clinical response was good-to-complete in five, fair in one, none in the remaining one. The in vitro results indicate that GVPL has optimal mucoadhesive and healing enhancer properties, maintained over time (up to 14 days); preliminary clinical results suggest that oral application of platelet lysate-loaded mucoadhesive formulation is feasible, safe, well tolerated, and effective. A larger controlled randomized study is needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vokurka S, Steinerova K, Karas M, Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant. 2009;44:601–5.
Blijlevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol. 200;17:605–10.
Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978.
van der Velden WJ, Herbers AH, Blijlevens NM. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant. 2009;43:85–6.
Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008;42:275–9.
Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant. 2007;39:347–52.
Crowther M, Avenell A, Culligan DJ. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant. 2009;44:413–25.
Mazzucco L, Medici D, Serra M, Panizza R, Rivara G, Orecchia S, et al. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion. 2004;44:1013–8.
Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, et al. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol. 2006;169:2254–65.
Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24:227–34.
Borzini P, Mazzucco L. Platelet gels and releasates. Curr Opin Hematol. 2005;12:473–9.
Bonferoni MC, Sandri G, Rossi S, Ferrari F, Gibin S, Caramella C. Chitosan citrate as multifunctional polymer for vaginal delivery. Evaluation of penetration enhancement and peptidase inhibition properties. Eur J Pharm Sci. 2008;5(33):166–76.
Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion. 2010;50:1359–69.
Lubrizol Pharmaceutical Bulletin 23: Bioadhesion, http://www.lubrizol.com/Pharmaceutical/Literature/Bulletins.html
Picardi A, Lanti A, Cudillo L, Cerretti R, Dentamaro T, De Angelis G, et al. Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant. Transfusion. 2009;50:501–6.
Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:175–83.
Acknowledgments
The authors wish to thank Cariplo Foundation for the financial support (Project title: “Platelet gel bioadhesive systems for mucositis in chemio/radio therapy and stem cell trasplantation” call 2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Del Fante, C., Perotti, C., Bonferoni, M.C. et al. Platelet Lysate Mucohadesive Formulation to Treat Oral Mucositis in Graft Versus Host Disease Patients: A New Therapeutic Approach. AAPS PharmSciTech 12, 893–899 (2011). https://doi.org/10.1208/s12249-011-9649-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-011-9649-3